Sign in

You're signed outSign in or to get full access.

RR

ReWalk Robotics Ltd. (RWLK)·Q4 2023 Earnings Summary

Executive Summary

  • Q4 2023 delivered record quarterly revenue of $6.9M, up 216% year over year; GAAP gross margin improved to 35.5%, while GAAP net loss was $(5.6)M or $(0.13) per share .
  • AlterG contributed $4.7M of Q4 revenue; legacy ReWalk products were $2.2M; integration is complete with expected $3M annual net savings in 2024 .
  • Lifeward (DBA) introduced 2024 guidance: revenue $28–$32M, non‑GAAP gross margin to high‑40%s, non‑GAAP operating loss falling to low double‑digit millions; Q1 2024 revenue guided to $5.0–$5.5M and excludes Medicare revenue .
  • CMS established exoskeletons in the Medicare brace benefit category effective Jan 1, 2024 and proposed preliminary reimbursement level for ReWalk Personal; final pricing expected in Q1 2024—key near‑term catalyst .

What Went Well and What Went Wrong

What Went Well

  • Record quarterly and annual revenue: Q4 revenue $6.9M; FY 2023 revenue $13.9M (151% YoY) driven by AlterG acquisition and improved product mix .
  • Integration completed with $3M annual net savings expected; management highlighted readiness to “maximize the opportunity” from new Medicare benefit category for exoskeletons .
  • GAAP gross margin improved to 35.5% in Q4; non‑GAAP adjusted gross margin of 47.0% reflects mix and adjustments (purchase accounting, inventory, amortization) .

Quotes:

  • “We expect 2024 to be a year of achievement as we transition into a growth phase…” — CEO Larry Jasinski .
  • “Commercial and operational integration… resulting in $3 million in annual net savings to be realized in 2024” .

What Went Wrong

  • GAAP operating loss widened YoY to $(6.1)M in Q4; GAAP net loss $(5.6)M; ongoing losses despite revenue scale .
  • Non‑GAAP gross margin fell 5.8pp YoY to 47.0% due to prior‑year favorable mix/material costs; indicates mix pressure even with integration benefits .
  • Cash used in operations remained significant: $(4.4)M in Q4; unrestricted cash fell to $28.1M at year‑end (from $32.6M at 9/30/23 and $58.2M at 6/30/23), reflecting spend and acquisition .

Financial Results

MetricQ2 2023Q3 2023Q4 2023
Revenue ($USD Millions)$1.337 $4.403 $6.884
GAAP Gross Profit ($USD Millions)$0.576 $0.863 $2.443
GAAP Gross Margin (%)43.1% 19.6% 35.5%
GAAP Operating Loss ($USD Millions)$(5.158) $(7.942) $(6.137)
GAAP Net Loss ($USD Millions)$(4.642) $(7.531) $(5.639)
Basic Net Loss per Share ($)$(0.08) $(0.13) $(0.13)

Non‑GAAP metrics:

MetricQ2 2023Q3 2023Q4 2023
Non‑GAAP Gross Profit ($USD Millions)$0.579 $1.985 $3.226
Non‑GAAP Gross Margin (%)43.3% 45.1% 47.0%
Non‑GAAP Operating Loss ($USD Millions)$(3.946) $(4.924) $(3.794)
Non‑GAAP Net Loss ($USD Millions)$(7.297) $(4.513) $(3.296)
Non‑GAAP Net Loss per Share ($)$(0.06) $(0.08) $(0.05)

Segment breakdowns:

Revenue by geography ($USD Millions):

RegionQ2 2023Q3 2023Q4 2023
United States$0.924 $2.497 $3.338
Europe$0.411 $1.466 $2.843
Asia Pacific$0.001 $0.094 $0.264
Rest of World$0.001 $0.346 $0.439
Total$1.337 $4.403 $6.884

Revenue by business ($USD Millions):

BusinessQ2 2023Q3 2023Q4 2023
Legacy ReWalk (Personal/Rehab/MyoCycle/ReStore)$1.337 $1.5 $2.2
AlterG (Anti‑Gravity Systems)$0.0 $2.9 $4.7
Total$1.337 $4.4 $6.9

Liquidity & cash KPIs:

KPIQ2 2023Q3 2023Q4 2023
Unrestricted Cash & Equivalents ($USD Millions)$58.184 $32.590 $28.083
DebtNone None None
Cash Used in Operations (Quarter) ($USD Millions)N/A$(7.4) $(4.4)

Non‑GAAP disclosure: Company uses non‑GAAP measures (gross margin, operating loss, net loss) excluding purchase accounting impacts, inventory write‑downs, amortization, M&A/restructuring, rebranding, earnout and stock‑based comp; reconciliations provided in Q4 press release .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue ($USD Millions)FY 2024Not provided$28–$32 New
Non‑GAAP Gross Margin (%)FY 2024Not providedHigh‑40%s New
Non‑GAAP Operating ExpensesFY 2024Not providedDecline from Q4’23 run‑rate New
Non‑GAAP Operating Loss ($USD Millions)FY 2024Not providedLow double‑digit millions New
Revenue ($USD Millions)Q1 2024Not provided$5.0–$5.5; excludes Medicare revenue New
Annual Net Savings ($USD Millions)2024Not provided$3 (integration synergies) New

Notes: Company does not provide GAAP reconciliations for non‑GAAP guidance due to unpredictability of items like stock‑based comp, acquisition‑related and earnout expenses .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2023)Previous Mentions (Q3 2023)Current Period (Q4 2023)Trend
Medicare reimbursement (CMS)Proposed rule to include exoskeletons; engagement ongoing Home Health Rule finalized; preliminary reimbursement proposed Benefit category effective Jan 1, 2024; final pricing expected in Q1 2024 Improving visibility; near‑term catalyst
AlterG integration/scalePending acquisition expected to contribute from Q3 Acquisition closed in Aug; $2.9M Q3 revenue; integration progress Integration complete; $4.7M Q4 revenue; $3M savings expected Synergies realized; revenue scaling
Margin dynamicsGM 43.1% with lower volume/mix GAAP GM 19.6%; non‑GAAP 45.1% on mix and AlterG contribution GAAP GM 35.5%; non‑GAAP 47.0%; YoY non‑GAAP margin down vs favorable PY mix GAAP improving; non‑GAAP steady mid‑40s
R&D pipelineNext‑gen ReWalk 7 progressing; 510(k) submission targeted by YE Significant progress toward submission; strategic milestones No new submission update; focus shifts to growth and Medicare opportunity Execution continuing; visibility unchanged
Corporate identity & brandingN/AInvestor presentation framing consolidation strategy –Rebranded to Lifeward; ticker change to LFWD Strategic repositioning complete

Management Commentary

  • “Our organizational integration work is now completed… ready to maximize the opportunity created by the newly established Medicare benefit category for exoskeletons…” — CEO Larry Jasinski .
  • “The past three months have been pivotal… acquired and began our integration of AlterG… we believe the future for ReWalk is very bright” — CEO Larry Jasinski (Q3) .
  • “With the recent addition of innovative solutions like the AlterG Anti‑Gravity systems… ReWalk Robotics into Lifeward speaks to the broader goal…” — CEO Larry Jasinski (Rebrand) .

Q&A Highlights

  • An archived webcast was provided, but a textual earnings call transcript for Q4 2023 was not available in our document corpus; no prepared Q&A content could be retrieved .
  • Guidance clarifications from the press release: Q1 2024 revenue excludes Medicare revenue; FY 2024 non‑GAAP metrics provided without GAAP reconciliation due to unpredictability of certain items .

Estimates Context

  • Wall Street consensus estimates via S&P Global were unavailable at the time of analysis due to CIQ mapping/limit errors; therefore, comparisons to consensus (EPS, revenue) cannot be provided. Values would have been retrieved from S&P Global if available.

Key Takeaways for Investors

  • Revenue inflection is real and predominantly AlterG‑driven; legacy ReWalk resumed growth to $2.2M in Q4, supporting broader portfolio scaling .
  • Margin profile improving on GAAP basis; sustained mid‑40s non‑GAAP gross margins suggest pricing/mix headroom post‑integration despite YoY non‑GAAP compression .
  • Opex discipline plus $3M synergies underpin FY 2024 non‑GAAP operating loss guided to low double‑digit millions—track quarterly run‑rate versus Q4 baseline .
  • CMS final pricing decision is a primary catalyst; Q1 guide excludes Medicare revenue—watch for incremental lifts starting mid‑year with AlterG NPI and Medicare phasing .
  • Liquidity at $28.1M (no debt) provides runway, but continued operating cash burn (Q4: $(4.4)M) necessitates execution on revenue/margin guidance and integration savings .
  • Rebrand to Lifeward and unified commercial infrastructure may accelerate clinic/customer engagement—monitor adoption across U.S./Europe segments .
  • Risk factors include ongoing GAAP losses, estimate uncertainty, and dependence on favorable CMS pricing/mix; align position sizing with regulatory timing and execution risk .